102 related articles for article (PubMed ID: 1623918)
1. Anti-arthritic effects demonstrated by an interleukin-2 receptor-targeted cytotoxin (DAB486IL-2) in rat adjuvant arthritis.
Bacha P; Forte SE; Perper SJ; Trentham DE; Nichols JC
Eur J Immunol; 1992 Jul; 22(7):1673-9. PubMed ID: 1623918
[TBL] [Abstract][Full Text] [Related]
2. DAB486IL-2 fusion toxin in refractory rheumatoid arthritis.
Sewell KL; Parker KC; Woodworth TG; Reuben J; Swartz W; Trentham DE
Arthritis Rheum; 1993 Sep; 36(9):1223-33. PubMed ID: 8216416
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
LeMaistre CF; Rosenblum MG; Reuben JM; Parkinson DR; Meneghetti CM; Parker K; Shaw JP; Deisseroth AB; Woodworth T
Lancet; 1991 May; 337(8750):1124-5. PubMed ID: 1674015
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis. A double-blind, placebo-controlled trial with open-label extension.
Moreland LW; Sewell KL; Trentham DE; Bucy RP; Sullivan WF; Schrohenloher RE; Shmerling RH; Parker KC; Swartz WG; Woodworth TG
Arthritis Rheum; 1995 Sep; 38(9):1177-86. PubMed ID: 7575710
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of an interleukin-2 fusion toxin (DAB486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy.
Tepler I; Schwartz G; Parker K; Charette J; Kadin ME; Woodworth TG; Schnipper LE
Cancer; 1994 Feb; 73(4):1276-85. PubMed ID: 8313331
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.
LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR
Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707
[TBL] [Abstract][Full Text] [Related]
7. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.
Phillips SM; Bhopale MK; Constantinescu CS; Ciric B; Hilliard B; Ventura E; Lavi E; Rostami A
J Neurol Sci; 2007 Dec; 263(1-2):59-69. PubMed ID: 17603081
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG
Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914
[TBL] [Abstract][Full Text] [Related]
9. Recombinant fusion toxins--a new class of targeted biologic therapeutics.
Woodworth TG; Nichols JC
Cancer Treat Res; 1993; 68():145-60. PubMed ID: 8105849
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human antigen-specific memory B cell response in vitro by a diphtheria toxin-related interleukin 2 fusion protein.
Grailer AP; Nichols JC; Strom TB; Sollinger HW; Burlingham WJ
Cell Immunol; 1991 Feb; 132(2):481-93. PubMed ID: 1988163
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 receptor-specific fusion toxin inhibits barotrauma-induced arterial atherosclerosis.
Miller DD; Bach RG; Tio FO; Bailey SR; Waters CA; Woodworth TG; Nichols JC; Paige SB; Farrar M
Atherosclerosis; 1996 Sep; 126(1):1-14. PubMed ID: 8879429
[TBL] [Abstract][Full Text] [Related]
12. Targeting diphtheria toxin to growth factor receptors.
Murphy JR; vanderSpek JC
Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of the diphtheria toxin/interleukin-2 fusion protein DAB486IL-2: efficacy in mycosis fungoides and other non-Hodgkin's lymphomas.
Kuzel TM; Rosen ST; Gordon LI; Winter J; Samuelson E; Kaul K; Roenigk HH; Nylen P; Woodworth T
Leuk Lymphoma; 1993 Nov; 11(5-6):369-77. PubMed ID: 8124209
[TBL] [Abstract][Full Text] [Related]
14. DAB389IL-2 suppresses autoimmune inflammation in the CNS and inhibits T cell-mediated lysis of glial target cells.
Bhopale MK; Hilliard B; Constantinescu CS; Fujioka T; Ventura E; Phillips SM; Rostami A
Exp Mol Pathol; 2014 Feb; 96(1):108-17. PubMed ID: 23872438
[TBL] [Abstract][Full Text] [Related]
15. Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study.
Foss FM; Borkowski TA; Gilliom M; Stetler-Stevenson M; Jaffe ES; Figg WD; Tompkins A; Bastian A; Nylen P; Woodworth T
Blood; 1994 Sep; 84(6):1765-74. PubMed ID: 8080984
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma.
Foss FM
Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a 90-minute infusion of the fusion toxin DAB486IL-2 in hematological cancers.
LeMaistre CF; Craig FE; Meneghetti C; McMullin B; Parker K; Reuben J; Boldt DH; Rosenblum M; Woodworth T
Cancer Res; 1993 Sep; 53(17):3930-4. PubMed ID: 8358720
[TBL] [Abstract][Full Text] [Related]
18. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats.
Case JP; Lorberboum-Galski H; Lafyatis R; FitzGerald D; Wilder RL; Pastan I
Proc Natl Acad Sci U S A; 1989 Jan; 86(1):287-91. PubMed ID: 2492102
[TBL] [Abstract][Full Text] [Related]
19. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.
Young DA; Hegen M; Ma HL; Whitters MJ; Albert LM; Lowe L; Senices M; Wu PW; Sibley B; Leathurby Y; Brown TP; Nickerson-Nutter C; Keith JC; Collins M
Arthritis Rheum; 2007 Apr; 56(4):1152-63. PubMed ID: 17393408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
